Detailed Narrative
Q2 FY26 Financial Performance and Margin Expansion
Gufic Biosciences reported a modest 1.3% sequential revenue growth to ₹230 crores in Q2 FY26. However, profitability saw significant improvement, with EBITDA increasing by 14.16% QoQ to ₹37.9 crores, and EBITDA margin expanding to 16.45% from 14.63%. PAT also grew by 23.14% QoQ to ₹14.9 crores, with PAT margin reaching 6.47%. This margin expansion was attributed to a higher contribution from the international business and improved sales mix.
Indore Facility Scale-up and Outlook
The Indore plant, which began commercial invoicing in October 2024 (Q1 FY26), is progressing as per plan, with 40 products having completed tech transfers and an additional 27 under development. Management expects the facility to achieve EBITDA break-even by Q4 FY26 and become margin accretive by FY27 onwards. The total CAPEX for Indore is around ₹350-355 crores, with a projected topline of ₹750-800 crores at 70-80% capacity utilization. EU GMP and UK MHRA approvals are targeted for Q1 FY27.
Domestic Business Segment Performance
The domestic business showed mixed performance. The infertility division (Ferticare) is a key growth driver, with Puregraf trending towards a ₹25 crore annual run rate and Supergraf towards ₹15 crore. Critical Care and Sparsh segments are growing at 8-10% in value, but net growth is 4-6% due to API price erosion. The healthcare business and Zenova are on a 10-15% growth trajectory. The Botulin Toxin business (Neuro & Aesthetic) is growing robustly at 22%.
International Business Expansion and Strategy
The international business demonstrated strong growth of 32-33% QoQ, driven by new market entries in regions like Canada, South Africa, and Brazil. Gufic Ireland secured its first marketing authorization in the EU, establishing a platform for future filings. The company received 24 key product and facility approvals across regulated and emerging markets. The strategy involves a disciplined, compliance-led approach to scale its complex injectable portfolio internationally, targeting 15-20% year-on-year growth.
Toxin Platform (Aesthaderm & Neurocare) Strategy
The Aesthaderm platform is expanding from toxins into a fuller aesthetic ecosystem, including fillers and bio-stimulators, with in-licensing for global quality products underway. Neurocare, the therapeutic toxin, focuses on creating new injectors and expanding indications. Management noted the Indian toxin market is small (₹18-20 million) but aims for a ₹100 crore business level, while acknowledging high upfront costs for international regulatory and clinical data for global expansion.
Capital Allocation and Debt Management
The company has no major CAPEX plans for the next two years. Current borrowing, including working capital and term loans, stands at ₹350-360 crores. Management expects this to reduce to ₹300-350 crores within two years, with additional working capital requirements for the Indore plant to be met through internal revenue generation. This indicates a focus on deleveraging and internal funding for growth.